Abbott Granted FDA Emergency Use Authorization for COVID-19 Antibody Blood Test on Alinity m System
By LabMedica International staff writers Posted on 13 May 2020 |
Image: The Alinity m system (Photo courtesy of Abbott)
Abbott (Lake Forest, IL, USA) has secured Emergency Use Authorization (EUA) from the US Food and Drug Administration (FDA) for the company's molecular test for the novel coronavirus (COVID-19) for use on its new Alinity m molecular laboratory instrument.
This was Abbott's fifth COVID-19 test to receive FDA EUA, helping to provide hospitals and labs across the US with broad, reliable molecular and antibody testing during this pandemic. The Alinity m system was cleared by the FDA for use with Abbott's HCV (hepatitis C) assay in late March.
The Alinity m system is an automated platform, which can run more tests in less time to give laboratories improved efficiency and flexibility. It is able to run up to 1,080 tests in 24 hours, while the company’s m2000 RealTime system can run up to 480 tests in 24 hours. Alinity m delivers true random access, allowing labs to run any test, any time for different types of infectious diseases while still providing results in less than two hours. This is especially critical during the COVID-19 pandemic when volume, speed and flexibility are needed. Abbott is working with hospitals and health systems in the US to install the new instrument, which will help keep up with the growing demand for testing.
"Molecular lab tests play a critical role in detecting the virus for COVID-19. As a leader in diagnostics, we are pushing forward to develop high-performing tests across our platforms to help combat this pandemic," said Robert B. Ford, president and chief executive officer, Abbott. "As we continue to develop and improve our testing technologies, we want to ensure they are meeting the needs of our customers – and right now that means having reliable tests for COVID-19 on all of our diagnostic instruments."
This was Abbott's fifth COVID-19 test to receive FDA EUA, helping to provide hospitals and labs across the US with broad, reliable molecular and antibody testing during this pandemic. The Alinity m system was cleared by the FDA for use with Abbott's HCV (hepatitis C) assay in late March.
The Alinity m system is an automated platform, which can run more tests in less time to give laboratories improved efficiency and flexibility. It is able to run up to 1,080 tests in 24 hours, while the company’s m2000 RealTime system can run up to 480 tests in 24 hours. Alinity m delivers true random access, allowing labs to run any test, any time for different types of infectious diseases while still providing results in less than two hours. This is especially critical during the COVID-19 pandemic when volume, speed and flexibility are needed. Abbott is working with hospitals and health systems in the US to install the new instrument, which will help keep up with the growing demand for testing.
"Molecular lab tests play a critical role in detecting the virus for COVID-19. As a leader in diagnostics, we are pushing forward to develop high-performing tests across our platforms to help combat this pandemic," said Robert B. Ford, president and chief executive officer, Abbott. "As we continue to develop and improve our testing technologies, we want to ensure they are meeting the needs of our customers – and right now that means having reliable tests for COVID-19 on all of our diagnostic instruments."
Latest COVID-19 News
- New Immunosensor Paves Way to Rapid POC Testing for COVID-19 and Emerging Infectious Diseases
- Long COVID Etiologies Found in Acute Infection Blood Samples
- Novel Device Detects COVID-19 Antibodies in Five Minutes
- CRISPR-Powered COVID-19 Test Detects SARS-CoV-2 in 30 Minutes Using Gene Scissors
- Gut Microbiome Dysbiosis Linked to COVID-19
- Novel SARS CoV-2 Rapid Antigen Test Validated for Diagnostic Accuracy
- New COVID + Flu + R.S.V. Test to Help Prepare for `Tripledemic`
- AI Takes Guesswork Out Of Lateral Flow Testing
- Fastest Ever SARS-CoV-2 Antigen Test Designed for Non-Invasive COVID-19 Testing in Any Setting
- Rapid Antigen Tests Detect Omicron, Delta SARS-CoV-2 Variants
- Health Care Professionals Showed Increased Interest in POC Technologies During Pandemic, Finds Study
- Set Up Reserve Lab Capacity Now for Faster Response to Next Pandemic, Say Researchers
- Blood Test Performed During Initial Infection Predicts Long COVID Risk
- Low-Cost COVID-19 Testing Platform Combines Sensitivity of PCR and Speed of Antigen Tests
- Finger-Prick Blood Test Identifies Immunity to COVID-19
- Quick Test Kit Determines Immunity Against COVID-19 and Its Variants